|
Post by nylefty on Aug 3, 2019 10:46:21 GMT -5
MannKind will be eligible to receive development and commercialization milestones of up to $102.25 million as well as mid-single to low double-digit royalties on net sales of product.
|
|
|
RLS
Aug 3, 2019 15:58:47 GMT -5
Post by ktim on Aug 3, 2019 15:58:47 GMT -5
Kevinmik on stocktwits said aphria had a great earning report and sp went up 40 percent. No doubt cannabis is the new hot fad or maybe the next new do it all drug. I see it advertised all over facebook. I sure feel like rls is missing out on a lot of easy money right now. Does anybody know what they are waiting for? How much longer before they can bring something to the market? "Does anybody know what they are waiting for?" I think Mike C. knows. I will say they have done a great job of keeping things secret. Everyday I check for the big press release and everyday it does not come. One day it will and I think sooner than later. If they are planning to be an FDA approved drug, where I believe the market for a cartridge based inhaler would lie, they are still a long ways off because they have to do clinical trials. First sign would be when they register the trial with FDA.
|
|
|
Post by akemp3000 on Aug 3, 2019 16:13:20 GMT -5
My swag guess is that RLS is bringing migraine and pain management inhalation to hospitals and hopefully the overall market. Al's wife suffered from migraines. Whereas Al's baby was diabetes and Afrezza, Andrea Leone-Bay's baby may have been pain management from the time she was working for Al. IF RLS has the financial horsepower behind it that some believe, and IF it truly cuts pain time significantly as in kidney stones, cancer and more, it could get fast tracked. All are big IF's but nice to imagine.
|
|
|
RLS
Aug 10, 2019 11:01:26 GMT -5
via mobile
cretin11 likes this
Post by sportsrancho on Aug 10, 2019 11:01:26 GMT -5
|
|